, Données globales d'épidémiologie des cancersEpidémiologie des cancers, p.17, 2018.

D. Sur, Unité Cancer et Environnement. Facteurs de risque de mésothéliome et cancer de la plèvre | Cancer et environnement, p.17, 2018.

L. Multigner, J. R. Ndong, A. Giusti, M. Romana, H. Delacroix-maillard et al., Chlordecone Exposure and Risk of Prostate Cancer, J Clin Oncol. 20 juill, vol.28, issue.21, pp.3457-62, 2010.
URL : https://hal.archives-ouvertes.fr/inserm-00518099

N. Taghizadeh, H. M. Boezen, J. P. Schouten, C. P. Schröder, E. De-vries et al., BMI and Lifetime Changes in BMI and Cancer Mortality Risk, PLoS ONE, vol.16, issue.2015, p.17, 2018.

M. S. Donaldson, Nutrition and cancer: A review of the evidence for an anti-cancer diet, Nutr J, vol.3, p.19, 2004.

M. S. Wiggins and E. M. Simonavice, Cancer prevention, aerobic capacity, and physical functioning in survivors related to physical activity: a recent review, Cancer Manag Res. 9 juin, vol.2, pp.157-64, 2010.

J. Connor, Alcohol consumption as a cause of cancer, Addict Abingdon Engl. févr, vol.112, issue.2, pp.222-230, 2017.

. Ministère-du-travail, . Emploi, L. De, and . Santé, Programme National nutrition santé, 2011.

, Avis du Conseil économique, social et environnemental, MM. Jean-Claude Etienne, Christian Corne. Les Enjeux de la prévention en matière de santé, Les éditions des Journaux Officiels. 21 févr 2012, p.17, 2016.

D. Sur,

L. Bourdillon, S. Luciano, and . Rey, L'état de santé de la population en FranceRapport, p.17, 2017.

D. Sur, Info Cancer. Le cancer à travers les âges, p.17, 2018.

D. Sur, , p.64

J. F. Pr and . Heron, Institut national du cancer. Détecter tôt pour mieux soigner -Se faire dépister, p.17, 2018.

J. Disponible-sur-;-solassol, N. Boulle, T. Maudelonde, and A. Mangé, Protéomique clinique$: vers la détection précoce des cancers$?, MS Médecine Sci, vol.21, issue.8-9, pp.722-730, 2005.

, Histoire Naturelle du Cancer

D. Sur,

L. Fondation-contre and . Cancer, Dépistage génétique du risque de cancer, p.17, 2018.

D. Sur, Immuno-oncologie. Les Cancers du sang et de la Moelle, des tumeurs « liquides, 2018.

C. Disponible-sur-;-moyret-lalle, R. Pommier, C. Bouard, E. Nouri, G. Richard et al., Plasticité des cellules cancéreuses et dissémination métastatique, médecine/sciences. 1 août, vol.32, issue.8-9, pp.725-756, 2016.

G. Christian and J. Brion, Le vaisseau tumoral$: une cible de choix

, Vers les stratégies thérapeutiques de demain, p.17, 2012.

M. Gozlan, Métastases$: la longue marche du cancer -Sciences et Avenir

, Duperray B, Junod B. Dépistage du cancer du sein. Une bonne intention, une mauvaise théorie, un résultat aberrant, Futura Sciences. Le cancer métastatique$: intravasation, extravasation et colonisation | Dossier, vol.2, pp.364-371, 2006.

C. Le and V. Richard, Anticancéreux$: Les points essentiels, 2018.

, Médecine Sorbonne université. Cancérologie Générale -Niveau DCEM3

J. P. Marie, Le phénomène de résistance multiple aux anticancéreux$: les gènes MDR et la P-gp, vol.6, pp.443-448

D. Sur, Gottesman MM, Pastan IH. The Role of Multidrug Resistance Efflux Pumps in Cancer: Revisiting a JNCI

G. Cancer, Cancer et système immunitaire, vol.18

. Futura and . Disponible,

G. Guasch, Dérégulation moléculaire et cancer$: prolifération, survie et inhibition de l'apoptose

D. Sur, rDeregulation&lang=FR&nbr=article 33. Futura Sciences. Résistance à la mort cellulaire$: exemple de l'apoptose

D. Sur,

J. Soria, S. Vignot, C. Massard, and O. Mir, Institut national du cancer. Quelle est la place des tests moléculaires dans le parcours de soins et le choix du traitement$? -Biomarqueurs et tests moléculaires, Lièvre A. Mutations du gène KRAS et réponse aux anticorps anti-EGFR dans les cancers colorectaux$: ce qu'il, pp.468-503, 2010.

B. Pabla, M. Bissonnette, and V. J. Konda, Colon cancer and the epidermal growth factor receptor: Current treatment paradigms, the importance of diet, and the role of chemoprevention, World J Clin Oncol, vol.6, issue.5, pp.133-174, 2015.

D. Hanahan and R. A. Weinberg, Hallmarks of cancer: the next generation, Cell. 4 mars, vol.144, issue.5, pp.646-74, 2011.

M. Bondarenko, Chimiothérapie métronomique: stratégie thérapeutique originale et prometteuse en oncologie pédiatrique, 2012.

D. Sur,

C. Leblanc, Quand la tumeur résiste à l'immunothérapie | UCLouvain

D. Sur, Société française de dermatologie. Patients atteints de mélanome de stade III inopérable ou de stade IV, vol.86, 2017.

S. Champiat and J. Soria, Service d'immunologie, Faculté de Pharmacie de Lille. Ipilimumab (YERVOY®) [Guide des anticorps monoclonaux à usage thérapeutique -Mars, vol.33, 2017.

D. Sur, Service d'immunologie, Faculté de Pharmacie de Lille. Nivolumab (OPDIVO® [Guide des anticorps monoclonaux à usage thérapeutique -Mars, 2018.

D. Sur, Fondation contre le Cancer. Comment augmenter l'efficacité de l'immunothérapie$?

D. Sur, Fondation EspeRare. À propos du repositionnement de médicaments | Fondation EspeRare

D. Sur,

F. Bertolini, V. P. Sukhatme, and G. Bouche, Drug repurposing in oncology-patient and health systems opportunities, Nat Rev Clin Oncol. déc, vol.12, issue.12, pp.732-774, 2015.

T. T. Ashburn and K. B. Thor, Drug repositioning: identifying and developing new uses for existing drugs, Nat Rev Drug Discov. août, vol.3, issue.8, pp.673-83, 2004.

J. W. Scannell, A. Blanckley, H. Boldon, and B. Warrington, Arrowhead Publishers. The 7th Annual Drug Repositioning, Repurposing and Rescue Conference, Brown AS, Patel CJ. A standard database for drug repositioning. Sci Data, vol.11, 2012.

D. Sur,

A. De-varax, M. Letellier, G. Börtlein, and A. , Étude relative aux médicaments orphelins, Drug repositioning | Anaxomics Biotech SL -Systems Biology Solutions

D. Sur,

D. Sur,

, Médecine Sorbonne Université. Les récepteurs béta-adrénergiques, agonistes et antagonistes, FMPMC-PS -Pharmacologie, 2018.

P. C. Brum, N. Rolim, A. Bacurau, and A. Medeiros, Neurohumoral activation in heart failure: the role of adrenergic receptors. An Acad Bras Ciênc, sept, vol.78, issue.3, pp.485-503, 2006.

C. Hoffmann, M. R. Leitz, S. Oberdorf-maass, M. J. Lohse, and K. Klotz, Comparative pharmacology of human ?-adrenergic receptor subtypes?characterization of stably transfected receptors in CHO cells, Naunyn Schmiedebergs Arch Pharmacol. 1 févr, vol.369, issue.2, pp.151-160, 2004.

A. Lecrubier, Pourquoi le propranolol a le statut de médicament orphelin dans l'angiosarcome

. Medscape, , p.22, 2017.

S. W. Cole, A. S. Nagaraja, S. K. Lutgendorf, P. A. Green, and A. K. Sood, Sympathetic nervous system regulation of the tumour microenvironment, Nat Rev Cancer. sept, vol.15, issue.9, pp.563-72, 2015.

E. Pasquier, J. Street, C. Pouchy, M. Carre, A. J. Gifford et al., ?-blockers increase response to chemotherapy via direct antitumour and anti-angiogenic mechanisms in neuroblastoma, Br J Cancer. 25 juin, vol.108, issue.12, pp.2485-94, 2013.

C. Léauté-labrèze, P. Hoeger, J. Mazereeuw-hautier, L. Guibaud, E. Baselga et al., A randomized, controlled trial of oral propranolol in infantile hemangioma, N Engl J Med. 19 févr, vol.372, issue.8, pp.735-781, 2015.

E. K. Sloan, S. J. Priceman, B. F. Cox, S. Yu, M. A. Pimentel et al., Sympathetic nervous system induces a metastatic switch in primary breast cancer, Cancer Res. 15 sept, vol.70, issue.18, pp.7042-52, 2010.

J. M. Stiles, C. Amaya, S. Rains, D. Diaz, R. Pham et al., Targeting of beta adrenergic receptors results in therapeutic efficacy against models of hemangioendothelioma and angiosarcoma, PloS One, vol.8, issue.3, p.60021, 2013.

S. Banavali, E. Pasquier, and N. Andre, Targeted therapy with propranolol and metronomic chemotherapy combination: sustained complete response of a relapsing metastatic angiosarcoma, Ecancermedicalscience, vol.9, p.499, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01420003

W. Chow, C. N. Amaya, S. Rains, M. Chow, E. B. Dickerson et al., Growth Attenuation of Cutaneous Angiosarcoma With Propranolol-Mediated ?-Blockade, JAMA Dermatol, vol.151, issue.11, pp.1226-1235, 2015.

E. Pasquier, N. André, J. Street, A. Chougule, B. Rekhi et al., Effective Management of Advanced Angiosarcoma by the Synergistic Combination of Propranolol and Vinblastine-based Metronomic Chemotherapy: A Bench to Bedside Study, EBioMedicine. avr, vol.6, pp.87-95, 2016.

. Clinicaltrials, Dose-Finding of Propranolol in Combination With Metronomic Fixed Oral Cyclophosphamide Based on Bivariate Efficacy-tolerability Outcome in Patients With Locally Advanced or Metastatic Angiosarcoma: A Collaborative and Innovative Phase I-II Sequential Trial by the French Sarcoma Group (GSF/GETO)

D. Sur,

G. Shakhar and S. Ben-eliyahu, In vivo beta-adrenergic stimulation suppresses natural killer activity and compromises resistance to tumor metastasis in rats, J Immunol Baltim Md 1950. 1 avr, vol.160, issue.7, pp.3251-3259, 1998.

J. P. Campbell, M. R. Karolak, Y. Ma, D. S. Perrien, S. K. Masood-campbell et al., Stimulation of host bone marrow stromal cells by sympathetic nerves promotes breast 68" cancer bone metastasis in mice, PLoS Biol. juill, vol.10, issue.7, p.1001363, 2012.

T. I. Barron, R. M. Connolly, L. Sharp, K. Bennett, and K. Visvanathan, Beta blockers and breast cancer mortality: a population-based study, J Clin Oncol Off J Am Soc Clin Oncol. 1 juill, vol.29, pp.2635-2679, 2011.

A. Montoya, C. N. Amaya, A. Belmont, N. Diab, R. Trevino et al., Use of non-selective ?-blockers is associated with decreased tumor proliferative indices in early stage breast cancer, Oncotarget, vol.8, issue.4, pp.6446-60, 2017.

. Clinicaltrials, Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy, p.22, 2018.

. Clinicaltrials, Perioperative Administration of COX 2 Inhibitors and Beta Blockers to Women Undergoing Breast Cancer Surgery

K. Masur, B. Niggemann, K. S. Zanker, and F. Entschladen, Norepinephrine-induced migration of SW 480 colon carcinoma cells is inhibited by beta-blockers, Cancer Res. 1 avr, vol.61, issue.7, pp.2866-2875, 2001.

C. Chin, J. Li, K. Lee, Y. Huang, K. Wang et al., Selective ?2-AR Blockage Suppresses Colorectal Cancer Growth Through Regulation of

. Signaling, G1-Phase Arrest, and Apoptosis, J Cell Physiol. févr, vol.231, issue.2, pp.459-72, 2016.

Q. Lin, F. Wang, R. Yang, X. Zheng, H. Gao et al., ClinicalTrials. ?-adrenergic Blocker and a COX2 Inhibitor for Prevention of Colorectal Cancer Recurrence, PloS One, vol.8, issue.4, p.22, 2013.

X. Liao, C. X. Zhao, W. Zhang, D. Long, H. Chaudhary et al., Effects of propranolol in combination with radiation on apoptosis and survival of gastric cancer cells in vitro, Radiat Oncol Lond Engl, vol.5, p.98, 2010.

X. Liao, C. X. Zhao, W. Zhang, D. Bi, T. Wang et al., The ?-adrenoceptor antagonist, propranolol, induces human gastric cancer cell apoptosis and cell cycle arrest via inhibiting nuclear factor ?B signaling, Oncol Rep. déc, vol.24, issue.6, pp.1669-76, 2010.

G. S. Bhattacharyya, A. Ranade, H. Malhotra, G. Babu, K. Shahid et al., Continuous metronomic temozolamide with propranolol and etodolac in recurrent globlastoma: A pilot study, J Clin Oncol. 20 mai, vol.32, issue.15_suppl, pp.13005-13005, 2014.

T. Shahid, G. S. Bhattacharyya, H. Malhotra, K. S. Govindbabu, P. M. Parikh et al., Continuous low dose temozolamide with or without VT-122 in glioblastoma, J Clin Oncol. 20 mai, vol.33, pp.13010-13010, 2015.

A. N. De-la-torre, I. Castaneda, A. F. Hezel, N. F. Bascomb, G. S. Bhattacharyya et al., Effect of coadministration of propranolol and etodolac (VT-122) plus sorafenib for patients with advanced hepatocellular carcinoma (HCC), J Clin Oncol. 20 janv, vol.33, 2015.

F. Hajighasemi and A. Mirshafiey, In vitro sensitivity of leukemia cells to propranolol, J Clin Med Res. août, vol.1, issue.3, pp.144-153, 2009.

B. Annabi, M. Lachambre, K. Plouffe, R. Moumdjian, and R. Béliveau, Propranolol adrenergic blockade inhibits human brain endothelial cells tubulogenesis and matrix metalloproteinase-9 secretion, Pharmacol Res, vol.60, issue.5, pp.438-483, 2009.

D. M. Lamkin, E. K. Sloan, A. J. Patel, B. S. Chiang, M. A. Pimentel et al., Chronic stress enhances progression of acute lymphoblastic leukemia via ?-adrenergic signaling, Brain Behav Immun. mai, vol.26, issue.4, pp.635-676, 2012.

M. Dal-monte, G. Casini, L. Filippi, G. P. Nicchia, M. Svelto et al., Functional involvement of ?3-adrenergic receptors in melanoma growth and vascularization, J Mol Med Berl Ger. déc, vol.91, issue.12, pp.1407-1426, 2013.

L. J. Wrobel, L. Gal, and F. A. , Inhibition of human melanoma growth by a noncardioselective ?-blocker, J Invest Dermatol. févr, vol.135, issue.2, pp.525-556, 2015.

H. Hasegawa and I. Saiki, Psychosocial stress augments tumor development through betaadrenergic activation in mice, Jpn J Cancer Res Gann. juill, vol.93, issue.7, pp.729-764, 2002.

A. Glasner, R. Avraham, E. Rosenne, M. Benish, O. Zmora et al., Improving survival rates in two models of spontaneous postoperative metastasis in mice by combined administration of a beta-adrenergic antagonist and a cyclooxygenase-2 inhibitor, J Immunol Baltim Md 1950. 1 mars, vol.184, issue.5, pp.2449-57, 2010.

. Clinicaltrials, Efficacy of Propranolol Treatment to Prevent Melanoma Progression, p.22, 2018.

I. Kozanoglu, M. K. Yandim, Z. B. Cincin, H. Ozdogu, B. Cakmakoglu et al., New indication for therapeutic potential of an old well-known drug (propranolol) for multiple myeloma, J Cancer Res Clin Oncol. févr, vol.139, issue.2, pp.327-362, 2013.

E. V. Yang, A. K. Sood, M. Chen, Y. Li, T. D. Eubank et al., Norepinephrine upregulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells, Cancer Res, vol.66, issue.21, pp.10357-64, 2006.

E. Pasquier, J. Street, C. Pouchy, M. Carre, A. J. Gifford et al., ?-blockers increase response to chemotherapy via direct antitumour and anti-angiogenic mechanisms in neuroblastoma, Br J Cancer. 25 juin, vol.108, issue.12, pp.2485-94, 2013.

J. K. Wolter, N. E. Wolter, A. Blanch, T. Partridge, L. Cheng et al., Antitumor activity of the beta-adrenergic receptor antagonist propranolol in neuroblastoma, Oncotarget. 15 janv, vol.5, issue.1, pp.161-72, 2014.

T. Xu, X. Xiao, S. Zheng, J. Zheng, H. Zhu et al., Antiangiogenic effect of propranolol on the growth of the neuroblastoma xenografts in nude mice, J Pediatr Surg. déc, vol.48, issue.12, pp.2460-2465, 2013.

. Clinicaltrials, Metronomic Treatment in Children and Adolescents With Recurrent or Progressive High Risk Neuroblastoma, Disponible sur: 70

. Clinicaltrials, Study of a Propranolol (HEMANGIOL®) and Oral Metronomic Vinorelbine (NAVELBINE®) Combination for Children and Teenagers With Refractory/Relapsing Solid Tumors

A. Han, A. , M. H. Schuller, and H. M. , Cooperative regulation of non-small cell lung carcinoma by nicotinic and beta-adrenergic receptors: a novel target for intervention, PloS One, vol.7, issue.1, p.29915, 2012.

D. G. Bernabé, A. C. Tamae, É. R. Biasoli, and S. Oliveira, Stress hormones increase cell proliferation and regulates interleukin-6 secretion in human oral squamous cell carcinoma cells, Brain Behav Immun. mars, vol.25, issue.3, pp.574-83, 2011.

N. E. Wolter, J. K. Wolter, D. J. Enepekides, and M. S. Irwin, Propranolol as a novel adjunctive treatment for head and neck squamous cell carcinoma, J Otolaryngol -Head Neck Surg J Oto-Rhino-Laryngol Chir Cervico-Faciale, vol.41, issue.5, pp.334-378, 2012.

S. K. Lutgendorf, S. Cole, E. Costanzo, S. Bradley, J. Coffin et al., Stressrelated mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines, Clin Cancer Res Off J Am Assoc Cancer Res, vol.9, issue.12, pp.4514-4535, 2003.

A. K. Sood, R. Bhatty, A. A. Kamat, C. N. Landen, L. Han et al., Stress hormone-mediated invasion of ovarian cancer cells, Clin Cancer Res Off J Am Assoc Cancer Res. 15 janv, vol.12, issue.2, pp.369-75, 2006.

J. Lee, M. Shahzad, Y. G. Lin, G. Armaiz-pena, L. S. Mangala et al., Surgical stress promotes tumor growth in ovarian carcinoma, Clin Cancer Res Off J Am Assoc Cancer Res. 15 avr, vol.15, issue.8, pp.2695-702, 2009.

. Clinicaltrials, Feasibility Study: Therapeutic Targeting of Stress Factors in Ovarian Cancer Patients

D. Sur,

K. Guo, Q. Ma, L. Wang, H. Hu, J. Li et al., Norepinephrine-induced invasion by pancreatic cancer cells is inhibited by propranolol, Oncol Rep, vol.22, issue.4, pp.825-855, 2009.

D. Zhang, Q. Ma, H. Hu, and M. Zhang, ?2-adrenergic antagonists suppress pancreatic cancer cell invasion by inhibiting CREB, NF?B and AP-1, Cancer Biol Ther. 1 juill, vol.10, issue.1, pp.19-29, 2010.

C. Kim-fuchs, C. P. Le, M. A. Pimentel, D. Shackleford, D. Ferrari et al., Chronic stress accelerates pancreatic cancer growth and invasion: a critical role for beta-adrenergic signaling in the pancreatic microenvironment, Brain Behav Immun. août, vol.40, pp.40-47, 2014.

L. I. Partecke, S. Speerforck, A. Käding, F. Seubert, S. Kühn et al., Chronic stress increases experimental pancreatic cancer growth, reduces survival and can be antagonised by beta-adrenergic receptor blockade, Pancreatol Off J Int Assoc Pancreatol IAP Al. juin, vol.16, issue.3, pp.423-456, 2016.

G. S. Bhattacharyya, K. G. Babu, S. A. Bondarde, G. Biswas, A. Ranade et al., Effect of coadministered beta blocker and COX-2 inhibitor to patients with pancreatic cancer prior to receiving albumin-bound (Nab) paclitaxel, J Clin Oncol. 20 janv, vol.33, pp.302-302, 2015.

D. Palm, K. Lang, B. Niggemann, T. L. Drell, K. Masur et al., The 71" norepinephrine-driven metastasis development of PC-3 human prostate cancer cells in BALB/c nude mice is inhibited by beta-blockers, Int J Cancer. 1 juin, vol.118, issue.11, pp.2744-2753, 2006.

. Clinicaltrials, Efficacy and Safety Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer

D. Sur,

P. Pantziarka, G. Bouche, V. Sukhatme, L. Meheus, I. Rooman et al., Repurposing Drugs in Oncology (ReDO)-Propranolol as an anti-cancer agent, vol.10, p.22, 2016.

J. Ishida, M. Konishi, N. Ebner, and J. Springer, Repurposing of approved cardiovascular drugs, J Transl Med. 20 sept, vol.14, issue.1, p.269, 2016.

E. Pasquier, J. Ciccolini, M. Carre, S. Giacometti, R. Fanciullino et al., Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment, Oncotarget, vol.2, issue.10, pp.797-809, 2011.

. Arcagy-gineco, Oncopédiatrie, tumeurs cérébrales de l'enfant, 2016.

. Gfme, . Médulloblastome, and . Pnet,

D. Sur, GFME. Glioblastome, tout savoir, origine, causes, diagnostic, pronostic, traitements, vaccins, 2018.

D. Sur,

, Dernières données mondiales sur le cancer$: le fardeau du cancer atteint 18,1 millions de nouveaux cas et 9,6 millions de décès par cancer en 2018. 12 sept, vol.3, 2018.

P. A. Ganz, L. A. Habel, E. K. Weltzien, B. J. Caan, and S. W. Cole, Examining the Influence of Beta Blockers and ACE Inhibitors on the Risk for Breast Cancer Recurrence: Results from the LACE Cohort, Breast Cancer Res Treat. sept, vol.129, issue.2, pp.549-56, 2011.

P. Chang, W. Huang, C. Lin, T. Huang, Y. Wu et al., Propranolol Reduces Cancer Risk, Medicine, vol.13, issue.2015

S. Banavali, E. Pasquier, and N. Andre, Targeted therapy with propranolol and metronomic chemotherapy combination: sustained complete response of a relapsing metastatic angiosarcoma, vol.8
URL : https://hal.archives-ouvertes.fr/hal-01420003

C. Léauté-labrèze, P. Hoeger, J. Mazereeuw-hautier, L. Guibaud, E. Baselga et al., Controlled Trial of Oral Propranolol in Infantile Hemangioma, N Engl J Med. 19 févr, vol.372, issue.8, pp.735-781, 2015.

J. Yi-wong and D. , Propranolol for infantile haemangioma |

Z. Dermnet-new, , 2012.

Y. Ji, S. Chen, Q. Wang, B. Xiang, Z. Xu et al., Intolerable side effects during propranolol therapy for infantile hemangioma: frequency, risk factors and management. Sci Rep, 2018.

, Disponible sur: 72, vol.8

. Clinicaltrials, Comparative Study to Evaluate the Effectiveness of Atenolol and Propranolol in the Treatment of Infantile Hemangiomas

D. Sur,

. Clinicaltrials, Nadolol Versus Propranolol in Children With Infantile Hemangiomas

. Pr and . Imbs, Study of a Propranolol (HEMANGIOL®) and Oral Metronomic Vinorelbine (NAVELBINE®) Combination for Children and Teenagers With Refractory/Relapsing Solid Tumors -Full Text View -ClinicalTrials, Chapitre 16-Les Betabloquants -Module de pharmacologie générale, 2003.

D. Sur,

. Clinicaltrials, Search of: propranolol | Recruiting, Not yet recruiting, Active, not recruiting, Enrolling by invitation Studies | Cancer -List Results

D. Sur,

A. Fund, Drug repurposing

. Anticancerfund, , 2017.

D. Sur,

. Inca, Le prix des médicaments anticancéreux, 2017.

P. M. Rothwell, M. Wilson, C. Elwin, B. Norrving, A. Algra et al., Longterm effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials, Lancet Lond Engl, vol.376, issue.9754, pp.1741-50, 2010.

H. Yasuda, M. Yamaya, K. Nakayama, T. Sasaki, S. Ebihara et al., Randomized phase II trial comparing nitroglycerin plus vinorelbine and cisplatin with vinorelbine and cisplatin alone in previously untreated stage IIIB/IV non-small-cell lung cancer, J Clin Oncol Off J Am Soc Clin Oncol. 1 févr, vol.24, issue.4, pp.688-94, 2006.

D. Eaton and R. E. Hawkins, Cimetidine in colorectal cancer -are the effects immunological or adhesion-mediated?, Br J Cancer. 21 janv, vol.86, issue.2, pp.159-60, 2002.

A. Saad, An open-label randomized controlled phase II study of clarithromycin (CL) plus CVP in patients (pts) with previously untreated stage III/IV indolent non Hodgkin lymphoma (NHL). janv, 2014.

, J Clin Oncol, vol.32, 2014.

F. Montanari, M. Lu, S. Marcus, A. Saran, A. Malankar et al., A Phase II Trial of Chloroquine in Combination with Bortezomib and Cyclophosphamide in Patients with Relapsed and Refractory Multiple Myeloma, Blood. 6 déc, vol.124, issue.21, pp.5775-5775, 2014.

F. Bertolini, V. P. Sukhatme, and G. Bouche, Drug repurposing in oncology: patient and 73" health systems opportunities

. Cancerworld, , 2016.

. Ministère-de-la-santé-du-burkina and . Faso, Plan stratégique de lutte contre le cancer 2013-2017, vol.74, 2013.

A. Renaud, Le cancer en Afrique, un tueur négligé mais redoutable

. Jeuneafrique and . Com, , p.14, 2017.

. Rfi-afrique, Au Burkina Faso, le Qatar va financer un centre de soins contre le cancer -RFI

. Rfi-afrique, , p.14, 2017.

F. Traore, B. Togo, E. Pasquier, A. Dembélé, and N. André, Preliminary evaluation of children treated with metronomic chemotherapy and valproic acid in a low-income country: Metro-Mali-02, Indian J Cancer. 7 janv, vol.50, issue.3, p.250, 2013.

C. Belorgey, J. Finzi, S. Negellen, T. Riquier, and M. Dahan, Rapport de l'INCA$: Développement des anticancéreux oraux/ Projections à court, moyen et long termes, p.40, 2016.

S. Dreyfus, Cancer$: les chimiothérapies orales changent la prise en charge

L. Mutualité-française, , 2016.

D. Sur,

M. Touraine and G. Fioraso, Plan cancer, 2014.

. Manuvie, Traitement anticancéreux oraux$: surmonter les difficultés de la prise en charge autonome pour accéder aux bienfaits thérapeutiques, 2017.

D. Sur, MOD=AJPERES&CACHEID=ROOTWOR KSPACE-b1192e9c

T. Marmorat, H. L. Canat, M. Préau, and F. Farsi, Dispenser des anticancéreux oraux à l'officine. Contraintes professionnelles et pistes d'actions. Santé Publique. 14 mars, vol.29, pp.89-93, 2017.

J. Moisan, L. Guillaumie, and L. Guénette, L'adhésion au traitement médicamenteux$: Concepts et moyens pour la maintenir ou l'améliorer. www.ProfessionSante.ca -Cahier de FC de l'actualité pharmaceutique, 2011.

. Iqvia, 'analyse mensuelle du marché des médicaments$: la transformation compliquée, 2018.

H. Autorité-de-santé, Commission de la transparence, Avis TEMERIT. 22 janv, 2014.

D. Sur,

H. Autorité-de-santé, Commission de la transparence, vol.22

D. Sur,

H. Autorité-de-santé, Commission de la transparence, 2012.

D. Sur,

, Ordre National des Pharmaciens. Le développement professionnel continu (DPC) -Nos missions

D. Sur,

. L'obs, Le cancer, un fléau en progression « alarmante » dans le monde

. L'obs, , 2018.